![]() |
|
|
Department of Biochemistry, Emory University School of Medicine
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: ubiquitin proteasome receptor stress-response apoptosis
| INTRODUCTION |
|---|
|
|
|---|
| Targeting Functions of the Ubiquitin Domain. |
|---|
|
|
|---|
Ubiquitin-like proteins also act as targeting signals.
The ubiquitin system is the prototype for a newly
recognized family of pathways that result in the covalent modification
of target proteins (Hodges et al. 1998
, Li & Hochstrasser 1999
). These systems all use the same regulatory
logic. A protein containing the ubiquitin-like domain and
containing a glycine at the C-terminus is covalently attached to
target proteins by at least five distinguishable systems. These systems
use different ubiquitin-like proteins, different enzymes and act on
different substrates, but share a common chemistry (Tanaka et al. 1998
). Covalent attachment of ubiquitin-like domains
has been implicated in the localization of proteins to the proteasome
and/or the endosome/lysosome pathways (ubiquitin), the nucleus
(SUMO-1/Smt3p), to the cytoskeleton (ISG15), to autophagic vesicles
(Apg12p) and in the recruitment of proteins to macromolecular complexes
(NEDD8/Rub1p). A number of other proteins contain a ubiquitin-like
domains but are not conjugated to other proteins (Tanaka et al. 1998
). Thus, ubiquitin-domains serve as versatile targeting
signals used in a number of cellular processes.
| Conjugation and Deconjugation of the Ubiquitin Domain. |
|---|
|
|
|---|
The conjugation of the ubiquitin domain is a reversible
process and the removal of the ubiquitin domain is catalyzed by
deubiquitinating enzymes (DUBs). These enzymes catalyze the hydrolysis
of the peptide bond at G76 of ubiquitin. There are at least 17 proteins
in yeast that are related to known deubiquitinating enzymes. Many more
are known to exist in higher eukaryotes. Why are there so many? One
possibility is that these enzymes have specificity for the type of
linkage in the polyubiquitin chains (i.e., K29, K48, or K63-linked
chains may be cleaved by different DUBs). They may also exhibit
specificity for different ubiquitin domains, although a new family of
deconjugating proteins specific for Smt3p has been identified
(Li & Hochstrasser 1999
). Thus, there may be so many of
these enzymes because of the number of different ubiquitin domains and
the variety in the way in which they can be polymerized.
This pathway of reversible modification resembles
phosphorylation in many respects. The enzymes that catalyze the
deconjugation of ubiquitin-like proteins from target proteins then
could serve the same regulatory roles as do phosphatases. These enzymes
would be proteases with specificity for cleavage of the isopeptide bond
formed upon modification, or with specificity for cleaving the peptide
bond of the pro-proteins to yield the mature ubiquitin-like
protein. A number of examples of processes regulated by DUBs are now
known (D'Andrea & Pellman 1998
, Wilkinson 1998
).
| Role of Ubiquitination in Regulating Signal Transduction. |
|---|
|
|
|---|
There are several steps in the internalization/degradation
pathway that may be regulated by ubiquitination. First, it has been
suggested that in some cases it is not the receptor, but another
nonreceptor protein that requires ubiquitination. A candidate protein
is Eps15, a protein that becomes phosphorylated, ubiquitinated, and
localized to the clathrin-coated pits upon ligand engagement of the
growth hormone or epidermal growth factor receptors (van Delft et al. 1997
). Second, some receptors such as the PDGF and CSF-1 receptors
induce the ubiquitination of a tyrosine kinase regulator, c-cbl
(Wang et al. 1999
). This protein has recently been shown
to participate in the endosomal sorting pathway by binding to and
enhancing the ubiquitination of the cytoplasmic domain of the
endocytosed receptors (Levkowitz et al. 1998
). Such
ubiquitinated receptors are localized to the lysosome for degradation,
while those that are not ubiquitinated are recycled to the cell
surface.
Upstream signal transduction events.
The classical phosphoinositide signaling system utilizes a
heterotrimeric G-protein coupled receptor to activate phospholipase
C, release Ca2+ and activate protein kinase C.
Monoubiquitination of Ca2+- calmodulin greatly reduces its
activation of a target kinase without causing the degradation of
calmodulin (Laub et al. 1998
). In yeast, the
G-protein coupled receptor itself is ubiquitinated and degraded
(Hicke 1999
). Similarly, there is evidence that the
inositol triphosphate receptors in the ER (Oberdorf et al. 1999
) and a variety of protein kinase C isoforms (Lu et al. 1998
) are substrates for ubiquitin-dependent
degradation upon activation of this pathway.
Tyrosine kinase activated receptor signaling is also
modulated by ubiquitination. Signaling by these receptors is through
both the Jak/STAT and the Ras/Map Kinase pathways. Signaling by IL-3 is
prolonged in the presence of proteasome inhibitors (Callus & Mathey-Prevot 1998
) and signaling by a number of other
pathways requires an intact ubiquitin pathway (Bonifacino & Weissman 1998
, Hicke 1999
, Strous & Govers 1999
). The reversal of ubiquitination is also important.
In drosophila, proper eye development requires intercellular
communication that is disrupted in mutants of faf, a deubiquitinating
enzyme. This mutation interacts genetically with the receptor tyrosine
kinase/Ras/MAP Kinase signaling pathway (Li et al. 1997
)
and the mammalian homolog of this DUB has been shown to bind to AF-6, a
Ras target involved in cell-cell adhesion (Taya et al. 1998
). Cytokine-induced signaling events have also been
shown to induce a family of mammalian deubiquitinating enzymes involved
in the regulation of growth (D'Andrea & Pellman 1998
).
These DUBs were shown to be immediate early gene products produced upon
cytokine stimulation, with each mechanistically distinct cytokine
inducing a different isozyme of this deubiquitinating enzyme. The JAK2
pathway is involved in transducing the signal and overexpression of
these enzymes results in suppression of growth. It seems likely that
the action of these DUBs is to deubiquitinate the cytoplasmic tail of
the internalized receptor to allow its return to the cell surface. This
"up-regulation" would be necessary to halt receptor degradation and
allow the cell to respond to the next bolus of cytokines that might be
encountered.
Downstream signal transduction events.
More than a dozen transcription factors are modulated by
ubiquitination ((Hershko & Ciechanover 1998
) and
references below). Ubiquitination has effects on the rate of
transcription factor generation including; those of the NF
B,
Wnt/Wingless and Hedgehog signaling pathways (Maniatis 1999
), the hypoxia-induced factor Hif1 (Huang et al. 1998
), and the unfolded protein response factor Hac1p
(Kaufman 1999
). The ubiquitin system has also been shown
to affect the half-life of the transcription factors Sp1 (Su et al. 1999
) fos, jun, myc, myb, myoD (Ciechanover et al. 1999
), the estrogen receptor, (Nawaz et al. 1999
) bcl-6 (Niu et al. 1998
), ß-catenin
(Easwaran et al. 1999
), ATF2 (Fuchs & Ronai 1999
) and tramtrack (Hu & Fearon 1999
). In the
case of STAT1(Callus & Mathey-Prevot 1998
), HAND
(Yamagishi et al. 1999
), and heat-shock factors
(Mathew et al. 1998
) the effects of ubiquitination are
not known in detail. A few examples of the role of ubiquitin in
transcription factor function are discussed below.
Two well-studied signaling pathways respond by
triggering ubiquitin-dependent proteolysis events that generate the
active form of the transcription factor. The best studied of these is
the NF
B pathway that is activated in response to a variety of
signals including cytokines, growth factors, oxidants, UV irradiation,
infections, and stress (Maniatis 1999
). TNF
action is
mediated by NIK (NF
B inducing kinase) while the HTLV-1 protein Tax
activates through the MEKK1 pathway. Both kinases have been shown to
phosphorylate IKK (I
B kinase) activating it to phosphorylate two
specific serines on I
B in the inactive I
B-NF
B complex. The
phosphorylated inhibitor dissociates from the complex and is
ubiquitinated by ß-TrCP, an analogue of Slimb involved in the
Wnt/Wingless pathway in drosophila. I
B is then degraded by an
ubiquitin-dependent pathway and the NF
B released is transported
to the nucleus where it activates a large number of genes. Another
regulator of transcription, ß-catenin is also a substrate for
ß-TrCP ubiquitin ligase. ß-catenin is a short-lived
multifunctional protein that participates in cadherin-mediated
cell-cell adhesion and in the transduction of the Wnt growth factor
signal that regulates development. When ß-catenin is allowed to
accumulate it enters the nucleus and binds to the high mobility group
box transcription factor LEF (lymphocyte-enhancer binding factor) and
directly regulates gene transcription (Easwaran et al. 1999
).
A third transcription factor, Hif-1
(hypoxia-inducible
transcription factor 1
) is constitutively synthesized and rapidly
degraded by an ubiquitin-dependent process in many cells
(Huang et al. 1998
). When the oxygen concentration
drops, Hif-1
becomes stable and is transported into the nucleus
where it associates with ARNT (aryl hydrocarbon receptor nuclear
transporter) and forms the active heterodimeric transcription factor
that induces the expression of erythropoietin, vascular endothelial
growth factor, and glycolytic enzymes. Hif-1
is a nonheme iron
protein and oxygen binding at this center is thought to be the signal
for ubiquitination by a multienzyme complex containing the elongin BC
complex, Cul2, and the von Hippel-Lindau tumor suppressor protein
(Lonergan et al. 1998
, Maxwell et al. 1999
). Mutations in the latter protein lead to a variety of
highly vascularized tumors in humans. It should be noted that elongin C
is a homolog of Skp1 and elongin B contains a ubiquitin-like domain
suggesting a similarity to the structure and function of the
Skp1/Cdc53/F-box class of ubiquitin ligases.
In most other cases, the exact nature of the regulation is not known, although it is common that the transcription factor itself is degraded by a ubiquitin-dependent pathway and that the ubiquitination is modulated by ligand binding or heterodimerization.
| Proteolysis to Repair Cellular Damage. |
|---|
|
|
|---|
ER quality control.
The degradation of abnormal ER and secretory proteins has
been shown to be ubiquitin-dependent in yeast and mammalian cells
(Plemper & Wolf 1999
). Yeast proteins resident to or
traversing the ER and that are misfolded or inappropriately
glycosylated undergo retrograde transport to the cytoplasm in a
reaction that requires the Sec61p transporter and other ER membrane
proteins. The protein is then ubiquitinated in a process requiring
Cue1p, Ubc6p and Ubc7p and is then degraded by the cytoplasmic
proteasome. A significant pool of proteasomes has been shown to be
perinuclear, suggesting that the machinery for this ubiquitination and
degradation may be localized at the ER membrane (Enenkel et al. 1999
). Thus, export and degradation may be tightly coupled.
Accumulation of unfolded proteins in the endoplasmic
reticulum (ER) activates an intracellular signaling pathway from the ER
to the nucleus (Kaufman 1999
), termed the unfolded
protein response (UPR). In yeast, the production of abnormal proteins
in the lumen of the ER results in the dimerization of Ire1p, a
transmembrane signaling molecule. Dimerization activates the
endonuclease activity of Ire1p and this activity initiates an unusual
cytoplasmic splicing reaction that results in higher levels of
translation of the Hac1 message (Kaufman 1999
). Hac1p is
normally kept at low levels by inefficient translation of the message
and ubiquitin-dependent proteolysis of the protein. The increased
levels of Hac1p bind to the UPR response element to induce the
synthesis of a variety of ER chaperones and the enzymes necessary to
expand the ER compartment to deal with the damaged proteins. The
pathway is similar, but more complicated, in mammalian cells.
The aggresome is a site for degradation of abnormal proteins.
When the cell is unable to deal with large amounts of
damaged or denatured proteins, these proteins appear to accumulate as
inclusions at the centrosome/microtubule organizing center
(Anton et al. 1999
, Wigley et al. 1999
).
This structure has been called the aggresome (Johnston et al. 1998
). Recent evidence suggests that the abnormal proteins
associate with the microtubules and are transported to the centrosome.
A significant fraction of the proteins are ubiquitinated and other
components of the ubiquitin pathway are also sequestered there,
including the ubiquitin binding protein p62, ubiquitin, the proteasome,
Hsp70 and Hsp90. It is not known if ubiquitination occurs before or
after aggregation but it is tempting to speculate that ubiquitination
may be a signal to dock to the microtubules and be transported to the
site(s) where proteasomes are abundant. The presence of the heat shock
proteins (Hsp) suggests that active refolding may also be an activity
of this structure or required for overall proteolysis. Clearly though,
this structure is intimately involved in degrading and perhaps
refolding damaged proteins that accumulate in the cytoplasm.
| Checkpoint Regulation: Repair vs. Apoptosis. |
|---|
|
|
|---|
When attempts to repair the damage are unsuccessful the
cells undergo apoptosis. There seem to be multiple ways to trigger this
pathway, including damage to the genome and signaling from the plasma
membrane receptors such as those for TNF or FAS. Proteasome inhibitors
have been variously reported to activate or inhibit apoptosis, although
it appears that some of the differences are due to the proliferative
state of the cells used (Drexler 1998
) and the levels of
inhibitor employed (Lin et al. 1998
). The
ubiquitin-like protein SUMO-1 and its E2 conjugating enzyme (Ubc9)
have been reported to bind to the intracellular domain of the TNF-R1
and Fas/APO1 receptors (Liou & Liou 1999
) and influence
apoptosis Finally, several substrates for ubiquitin-mediated
proteolysis also regulate apoptosis, notably: p53 (Amundson et al. 1998
, Scheffner 1998
), NF
B/I
B
(Maniatis 1999
), bcl2 (Dimmeler et al. 1999
), bax, mdm2(Chang et al. 1998
), c-myc
and E2F-1 (Hengstschlager et al. 1999
).
| Summary. |
|---|
|
|
|---|
Address correspondence to: 4017 Rollins Research Building, Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322-3050
| FOOTNOTES |
|---|
2 Manuscript received 8 September 1999 ![]()
4 Amino acids are shown using the one-letter
code. Proteins from yeast end with the suffix p. Ubiquitin-like
proteins and their accession numbers are: SUMO-1, Swiss:Q93068; Smt3p,
Swiss:Q12306; ISG15, Swiss:P05161; Apg12p, PIR:S46093; Nedd8,
Swiss:Q15843; Rub1p, Swiss:Q03919. Other abbreviations are: APC/C, an
E3 ubiquitin ligase complex known as the Anaphase promoting complex or
the cyclosome; ß-TrCP, beta-transducin repeat-containing
protein; UPR, unfolded protein response; DUBs, deubiquitinating
enzymes; E1, ubiquitin activating enzyme; E2, ubiquitin conjugating
enzyme; E3, ubiquitin protein ligase; E6AP, the E3 ubiquitin ligase
known as E6 associated protein; ER, endoplasmic reticulum;
HECT-domain, homology to E6AP C-terminus; Hsp, heat shock protein;
IKK, I
B kinase; IL-3, interleukin 3; NIK, NF
B inducing kinase;
PA700, the 19S regulator complex of the proteasome. SCF, an E3
ubiquitin ligase complex containing Skp1p, Cdc53p, Roc1p, and an
F-box containing protein. ![]()
| REFERENCES |
|---|
|
|
|---|
1. Amundson S. A., Myers T. G., Fornace A. J., Jr Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene 1998;17:3287-3299[Medline]
2.
Anton L. C., Schubert U., Bacik I., Princiotta M. F., Wearsch P. A., Gibbs J., Day P. M., Realini C., Rechsteiner M. C., Bennink J. R., Yewdell J. W. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell Biol. 1999;146:113-124
3. Bonifacino J. S., Weissman A. M. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu. Rev. Cell Dev. Biol. 1998;14:19-57[Medline]
4.
Callus B. A., Mathey-Prevot B. Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. Blood 1998;91:3182-3192
5. Chang Y. C., Lee Y. S., Tejima T., Tanaka K., Omura S., Heintz N. H., Mitsui Y. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differen 1998;9:79-84[Abstract]
6. Ciechanover A., Breitschopf K., Hatoum O. A., Bengal E. Degradation of MyoD by the ubiquitin pathway: regulation by specific DNA-binding and identification of a novel site for ubiquitination. Mol. Biol. Rep. 1999;26:59-64[Medline]
7. D'Andrea A., Pellman D. Deubiquitinating enzymes: A new class of biological regulators. Crit. Rev. Biochem. Mol. Biol. 1998;33:337-352[Medline]
8.
Dimmeler S., Breitschopf K., Haendeler J., Zeiher A. M. Dephosphorylation targets bcl-2 for ubiquitin-dependent degradation: A link between the apoptosome and the proteasome pathway. J. Exp. Med. 1999;189:1815-1822
9. Drexler H.C.A. Programmed cell death and the proteasome. Apoptosis 1998;3:1-7[Medline]
10.
Easwaran V., Song V., Polakis P., Byers S. The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin- lymphocyte enhancer-binding factor signaling. J. Biol. Chem. 1999;274:16641-16645
11. Enenkel C., Lehmann A., Kloetzel P. M. GFP-labelling of 26S proteasomes in living yeast: insight into proteasomal functions at the nuclear envelope/rough ER. Mol. Biol. Rep. 1999;26:131-135[Medline]
12.
Fuchs S. Y., Ronai Z. Ubiquitination and degradation of ATF2 are dimerization dependent. Mol. Cell. Biol. 1999;19:3289-3298
13.
Glickman M. H., Rubin D. M., Fried V. A., Finley D. The regulatory particle of the Saccharomyces cerevisiae proteasome. Mol. Cell. Biol. 1998;18:3149-3162
14. Hengstschlager M., Holzl G., Hengstschlager-Ottnad E. Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle. Oncogene 1999;18:843-848[Medline]
15. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998;67:425-479[Medline]
16. Hicke L. Gettin' down with ubiquitin: Turning off cell-surface receptors, transporters and channels. Trends Cell Biol 1999;9:107-112[Medline]
17. Hodges M., Tissot C., Freemont P. S. Protein regulation: Tag wrestling with relatives of ubiquitin. Curr. Biol. 1998;8:R749-R752[Medline]
18.
Hu G., Fearon E. R. Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins. Mol. Cell. Biol. 1999;19:724-732
19.
Huang L. E., Gu J., Schau M., Bunn H. F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 1998;95:7987-7992
20.
Johnston J. A., Ward C. L., Kopito R. R. Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 1998;143:1883-1898
21.
Kaufman R. J. Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev 1999;13:1211-1233
22. Koegl M., Hoppe T., Schlenker S., Ulrich H. D., Mayer T. U., Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999;96:635-644[Medline]
23. Kopito R. R. Biosynthesis and degradation of CFTR. Physiol. Rev. 1999;79:S167-S173
24. Lakin N. D., Hann B. C., Jackson S. P. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 1999;18:3989-3995[Medline]
25. Laub M., Steppuhn J. A., Bluggel M., Immler D., Meyer H. E., Jennissen H. P. Modulation of calmodulin function by ubiquitin-calmodulin ligase and identification of the responsible ubiquitylation site in vertebrate calmodulin. Eur. J. Biochem. 1998;255:422-431[Medline]
26.
Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W. Y., Beguinot L., Geiger B., Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998;12:3663-3674
27.
Li Q., Hariharan I. K., Chen F., Huang Y., Fischer J. A. Genetic interactions with Rap1 and Ras1 reveal a second function for the fat facets deubiquitinating enzyme in Drosophila eye development. Proc. Natl. Acad. Sci. U.S.A. 1997;94:12515-12520
28. Li S. J., Hochstrasser M. A new protease required for cell-cycle progression in yeast. Nature 1999;398:246-251[Medline]
29. Lin K. I., Baraban J. M., Ratan R. R. Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ 1998;5:577-583[Medline]
30.
Liou M. L., Liou H. C. The ubiquitin-homology protein, DAP-1, associates with tumor necrosis factor receptor (p60) death domain and induces apoptosis. J. Biol. Chem. 1999;274:10145-10153
31.
Lonergan K. M., Iliopoulos O., Ohh M., Kamura T., Conaway R. C., Conaway J. W., Kaelin W. G., Jr Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 1998;18:732-741
32.
Lu Z., Liu D., Hornia A., Devonish W., Pagano M., Foster D. A. Activation of protein kinase C triggers its ubiquitination and degradation. Mol. Cell. Biol. 1998;18:839-845
33.
Maniatis T. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 1999;13:505-510
34.
Mathew A., Mathur S. K., Morimoto R. I. Heat shock response and protein degradation: Regulation of HSF2 by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 1998;18:5091-5098
35. Maxwell P. H., Wiesener M. S., Chang G. W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275[Medline]
36.
Nawaz Z., Lonard D. M., Dennis A. P., Smith C. L., O'Malley B. W. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 1999;96:1858-1862
37.
Niu H., Ye B. H., Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 1998;12:1953-1961
38. Oberdorf J., Webster J. M., Zhu C. C., Luo S. G., Wojcikiewicz R. J. Down-regulation of types I, II and III inositol 1,4,5-trisphosphate receptors is mediated by the ubiquitin/proteasome pathway. Biochem. J. 1999;339:453-461
39. Orlowski R. Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 1999;6:303-313[Medline]
40. Pickart C. M. Targeting of substrates to the 26S proteasome. FASEB J 1997;11:1055-1066[Abstract]
41. Plemper R. K., Wolf D. H. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem. Sci. 1999;24:266-270[Medline]
42. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol.Ther. 1998;78:129-139[Medline]
43. Schwartz A. L., Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 1999;50:57-74[Medline]
44. Strous G. J., Govers R. The ubiquitin-proteasome system and endocytosis. J. Cell Sci. 1999;112:1417-1423[Abstract]
45.
Su K., Roos M. D., Yang X., Han I., Paterson A. J., Kudlow J. E. An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. J. Biol. Chem. 1999;274:15194-15202
46.
Tanaka K. Proteasomes: structure and biology. J. Biochem.(Tokyo). 1998;123:195-204
47. Tanaka K., Suzuki T., Chiba T. The ligation systems for ubiquitin and ubiquitin-like proteins. Molec. Cells 1998;8:503-512
48.
Taya S., Yamamoto T., Kano K., Kawano Y., Iwamatsu A., Tsuchiya T., Tanaka K., Kanai-Azuma M., Wood S.A., Mattick J.S., Kaibuchi K. The Ras target AF-6 is a substrate of the fam deubiquitinating enzyme. J. Cell Biol. 1998;142:1053-1062
49.
Tinker-Kulberg R. L., Morgan D. O. Pds1 and esp1 control both anaphase and mitotic exit in normal cells and after DNA damage. Genes Dev 1999;13:1936-1949
50.
van Delft S., Govers R., Strous G. J., Verkleij A. J., van Bergen en Henegouwen P. M. Epidermal growth factor induces ubiquitination of Eps15. J. Biol. Chem. 1997;272:14013-14016
51. Wang Y., Yeung Y. G., Stanley E. R. CSF-1 stimulated multiubiquitination of the CSF-1 receptor and of Cbl follows their tyrosine phosphorylation and association with other signaling proteins. J. Cell. Biochem. 1999;72:119-134[Medline]
52.
Wigley W. C., Fabunmi R. P., Lee M. G., Marino C. R., Muallem S., DeMartino G. N., Thomas P. J. Dynamic association of proteasomal machinery with the centrosome. J. Cell Biol 1999;145:481-490
53. Wilkinson K. D. Cellular Regulation by Ubiquitin-Dependent Processes. Adv. Mol. Cell Biol. 1998;27:71-104
54.
Yamagishi H., Garg V., Matsuoka R., Thomas T., Srivastava D. A molecular pathway revealing a genetic basis for human cardiac and craniofacial defects. Science 1999;283:1158-1161
This article has been cited by other articles:
![]() |
G. Xu, C. Sztalryd, X. Lu, J. T. Tansey, J. Gan, H. Dorward, A. R. Kimmel, and C. Londos Post-translational Regulation of Adipose Differentiation-related Protein by the Ubiquitin/Proteasome Pathway J. Biol. Chem., December 30, 2005; 280(52): 42841 - 42847. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. St-Arnaud Ubiquitin Ligase: What Is Your True Substrate? IBMS BoneKEy, July 1, 2005; 2(7): 6 - 10. [Full Text] [PDF] |
||||
![]() |
M. B. Reid Response of the ubiquitin-proteasome pathway to changes in muscle activity Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1423 - R1431. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Misaghi, P. J. Galardy, W. J. N. Meester, H. Ovaa, H. L. Ploegh, and R. Gaudet Structure of the Ubiquitin Hydrolase UCH-L3 Complexed with a Suicide Substrate J. Biol. Chem., January 14, 2005; 280(2): 1512 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
Session 7: Ubiquitin & Proteasomes Toxicol Pathol, October 1, 2004; 32(6): 740 - 742. [PDF] |
||||
![]() |
G. R. Beck Jr. and N. Knecht Osteopontin Regulation by Inorganic Phosphate Is ERK1/2-, Protein Kinase C-, and Proteasome-dependent J. Biol. Chem., October 24, 2003; 278(43): 41921 - 41929. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Gan-Erdene, K. Nagamalleswari, L. Yin, K. Wu, Z.-Q. Pan, and K. D. Wilkinson Identification and Characterization of DEN1, a Deneddylase of the ULP Family J. Biol. Chem., August 1, 2003; 278(31): 28892 - 28900. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kachroo, M. E. Nasrallah, and J. B. Nasrallah Self-Incompatibility in the Brassicaceae: Receptor-Ligand Signaling and Cell-to-Cell Communication PLANT CELL, May 1, 2002; 14(90001): S227 - 238. [Full Text] [PDF] |
||||
![]() |
B. M. Stramer, J. R. Cook, M. E. Fini, A. Taylor, and M. Obin Induction of the Ubiquitin-Proteasome Pathway during the Keratocyte Transition to the Repair Fibroblast Phenotype Invest. Ophthalmol. Vis. Sci., July 1, 2001; 42(8): 1698 - 1706. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yan, J. H. Doelling, T. G. Falbel, A. M. Durski, and R. D. Vierstra The Ubiquitin-Specific Protease Family from Arabidopsis. AtUBP1 and 2 Are Required for the Resistance to the Amino Acid Analog Canavanine Plant Physiology, December 1, 2000; 124(4): 1828 - 1843. [Abstract] [Full Text] |
||||
![]() |
M. H. Tatham, E. Jaffray, O. A. Vaughan, J. M. P. Desterro, C. H. Botting, J. H. Naismith, and R. T. Hay Polymeric Chains of SUMO-2 and SUMO-3 Are Conjugated to Protein Substrates by SAE1/SAE2 and Ubc9 J. Biol. Chem., September 14, 2001; 276(38): 35368 - 35374. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||